

RealRate

PHARMACEUTICAL 2018

CAMBREX CORP Rank 41 of 342







RealRate

PHARMACEUTICAL 2018

CAMBREX CORP Rank 41 of 342

The relative strengths and weaknesses of CAMBREX CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CAMBREX CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 113% points. The greatest weakness of CAMBREX CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 225%, being 179% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	422,078
Cost of Goods Sold	0
Intangible Assets	57,494
Liabilities, Current	82,541
Liabilities, Non-Current	25,213
Other Assets	6,694
Other Compr. Net Income	23,292
Other Expenses	342,430
Other Liabilities	87,947
Other Net Income	-2,207
Other Revenues	534,456
Property and Equipment	254,299
Research and Development	16,901
Selling, General and Administrative Expense	70,468

Output Variable	Value in 1000 USD
Assets	740,565
Liabilities	195,701
Expenses	429,799
Revenues	534,456
Stockholders Equity	544,864
Net Income	102,450
Comprehensive Net Income	114,096
Economic Capital Ratio	225%

